menu
    • menu
    [{"orgOrder":0,"company":"Senti Biosciences","sponsor":"RoosterBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Human mesenchymal stem\/stromal cell therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ RoosterBio","highestDevelopmentStatusID":"1","companyTruncated":"Senti Biosciences \/ RoosterBio"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"SENTI-101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Dynamics Special Purpose Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"SENTI-202","moa":"CD33","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Senti Biosciences \/ Dynamics Special Purpose Corp","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Dynamics Special Purpose Corp"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-301","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"IL-15","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"IL-15","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"SENTI-202","moa":"IL-15","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-401","moa":"VSIG2","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"GeneFab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Senti Biosciences \/ GeneFab","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ GeneFab"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celest Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"SENTI-301A","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Celest Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Senti Biosciences \/ Celest Therapeutics"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SENTI-202","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cytarabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senti Biosciences","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"14","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"SENTI-202","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Senti Biosciences","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicines","highestDevelopmentStatusID":"14","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by Senti Biosciences

    Menu

    Senti Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : California Institute for Regenerative Medicines

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Senti Bio Announces Grant Award from CIRM for SENTI-202 Clinical Development

                            Details : The CIRM grant will support the ongoing clinical development of SENTI-202, which is being evaluated in early-stage clinical trial studies for treating acute myeloid leukemia.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 05, 2024

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : California Institute for Regenerative Medicines

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202,Cytarabine,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : California Institute for Regenerative Medicines

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Senti Bio Awarded CIRM Grant for Logic Gated CAR-NK Cell Therapy

                            Details : The proceeds will advance the development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, for relapsed/refractory hematologic malignancies including AML.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 01, 2024

                            Lead Product(s) : SENTI-202,Cytarabine,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : California Institute for Regenerative Medicines

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senti Bio Doses First Patient in Phase 1 Trial of SENTI-202 for Hematologic Malignancies

                            Details : SENTI-202 is a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as acute myeloid leukemia.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 13, 2024

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory...

                            Details : SENTI-202 is an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 22, 2023

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

                            Details : SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells. It is being evaluated for the treatment of acute myeloid leukemia (AML).

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 05, 2023

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-301A

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Celest Therapeutics

                            Deal Size : $156.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301...

                            Details : Under the collaboration, Celest will lead clinical development for the advancement of SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of GPC3 expressing tumors.

                            Brand Name : SENTI-301A

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : SENTI-301A

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Celest Therapeutics

                            Deal Size : $156.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : GeneFab

                            Deal Size : $38.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufa...

                            Details : Under the partnership, GeneFab will support manufacturing of Senti’s chimeric antigen receptor natural killer (CAR-NK) medicines pipeline, including SENTI-202, for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as AML and M...

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $38.0 million

                            August 10, 2023

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : GeneFab

                            Deal Size : $38.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

                            Details : Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-401

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

                            Details : SENTI-401 is designed to incorporate logic gating to target and kill CEA-expressing tumor cells, while preventing the killing of CEA-expressing healthy epithelial cells for the treatment of colorectal cancer (CRC).

                            Brand Name : SENTI-401

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : SENTI-401

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Senti Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Leaps by Bayer

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combinatio...

                            Details : Senti’s existing investors continue to support the mission of engineering gene circuits with programmable logic in cell and gene therapies, and progress in advancing multiple oncology programs including SENTI-202, towards the clinic.

                            Brand Name : SENTI-202

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 24, 2022

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Leaps by Bayer

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth